Jacobs Levy Equity Management Inc. Has $851,000 Stock Holdings in Sangamo Therapeutics, Inc. $SGMO

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Sangamo Therapeutics by 74.8%, acquiring an additional 555,323 shares to own approximately 1,297,785 shares total, valued at around $851,000.
• Several hedge funds, including Captrust Financial Advisors and Cerity Partners LLC, have recently made significant changes to their positions in Sangamo, with institutional investors now owning 56.93% of the company.
• Sangamo Therapeutics shares are trading around $0.50, with an average analyst rating of "Moderate Buy" and a price target of $4.50, despite a reported loss of ($0.08) EPS in the recent quarter.

Jacobs Levy Equity Management Inc. raised its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 74.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,297,785 shares of the biopharmaceutical company's stock after purchasing an additional 555,323 shares during the period. Jacobs Levy Equity Management Inc. owned 0.57% of Sangamo Therapeutics worth $851,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Captrust Financial Advisors bought a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $30,000. Cerity Partners LLC grew its position in Sangamo Therapeutics by 439.2% in the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 44,800 shares in the last quarter. Caption Management LLC acquired a new position in shares of Sangamo Therapeutics during the 1st quarter worth $37,000. Lazard Asset Management LLC bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $47,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Sangamo Therapeutics in the 1st quarter valued at $47,000. Institutional investors own 56.92% of the company's stock.

Sangamo Therapeutics Stock Down 0.9%

Shares of SGMO stock traded down $0.00 during mid-day trading on Monday, reaching $0.50. The stock had a trading volume of 3,665,516 shares, compared to its average volume of 4,047,623. The firm has a market cap of $150.95 million, a PE ratio of -1.73 and a beta of 1.20. Sangamo Therapeutics, Inc. has a one year low of $0.41 and a one year high of $3.18. The firm's 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.61.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. Sell-side analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SGMO has been the topic of several recent research reports. Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 4th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.